rewrite this title and make it good for SEOApogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug

We recently compiled a list of 11 Best Future Stocks to Buy Now. Apogee Therapeutics, Inc. stands fourth on our list.

Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotech company developing novel antibody-based therapies for inflammatory and immunology (I&I) conditions, including atopic dermatitis (AD), asthma, eosinophilic esophagitis, and COPD. Using advanced antibody engineering, the company aims to improve efficacy and extend dosing intervals, addressing major unmet needs in these large markets.

In July 2025, Apogee Therapeutics, Inc. (NASDAQ:APGE) reported positive 16-week results from its Phase 2 APEX trial of APG777, an anti-IL-13 antibody for moderate-to-severe AD. The data demonstrated strong efficacy and safety, positioning APG777 as a potential best-in-class therapy with differentiated dosing advantages. The company held a webcast on July 7 to discuss these promising results, which support advancing the candidate to later-stage trials.

A biotechnologist in a lab coat discussing a therapeutic antibody with a colleague.

The business’s pipeline also includes APG990, which showed favorable pharmacokinetics in Phase 1 trials, suggesting it could be administered as infrequently as every three to six months. The combination of APG777 and APG990 reflects Apogee Therapeutics, Inc. (NASDAQ:APGE)’s strategy to deliver long-acting, highly effective treatments for chronic inflammatory diseases.

While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.